Jeffrey M Jacobson
Affiliation: Drexel University College of Medicine
- Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adultsJeffrey M Jacobson
Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, 245 N 15th St, MS 461, Philadelphia, PA 19104, USA
Antimicrob Agents Chemother 54:4137-42. 2010..The findings further delineate the safety and antiviral properties of this novel, long-acting antiretroviral agent...
- Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adultsJeffrey M Jacobson
Drexel University College of Medicine, Philadelphia, PA 19104, USA
J Infect Dis 198:1345-52. 2008..The chemokine receptor CCR5 provides an entry portal for HIV-1, and PRO 140 is a humanized monoclonal antibody that binds to CCR5 and potently inhibits CCR5-tropic (R5) HIV-1 in vitro...
- Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adultsJeffrey M Jacobson
Drexel University College of Medicine, Philadelphia, PA 19102, USA
Antimicrob Agents Chemother 53:450-7. 2009..In conclusion, ibalizumab administered either weekly or biweekly was safe and well tolerated and demonstrated antiviral activity. Further studies with ibalizumab in combination with standard antiretroviral treatments are warranted...
- Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibodyJeffrey M Jacobson
Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania 19104, USA
J Infect Dis 201:1481-7. 2010..This study is the first to evaluate subcutaneous administration...
- Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infectionChristopher J Bruno
Division of Infectious Diseases and HIV Medicine, Department of Medicine, Drexel University College of Medicine, Philadelphia, PA, USA
J Antimicrob Chemother 65:1839-41. 2010..Its unique mode of action reduces the risk of cross-resistance with currently available antiretroviral agents, with the potential to expand the choices available to treat drug-resistant HIV-1...
- Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trialNoah McKittrick
University of Pennsylvania, Philadelphia, PA 19104, USA
Ann Intern Med 158:19-26. 2013..HIV-infected persons have less robust antibody responses to influenza vaccines...
- Combinatorial approaches to the prevention and treatment of HIV-1 infectionVanessa Pirrone
Department of Microbiology and Immunology, Drexel University College of Medicine, 245 N 15th Street, New College Building, Philadelphia PA 19102, USA
Antimicrob Agents Chemother 55:1831-42. 2011..The shift in focus within the microbicide development field from single compounds to combination approaches is also explored...
- Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integrationLivio Azzoni
1HIV 1 Immunopathogenesis Laboratory, The Wistar Institute, Philadelphia, PA, USA
J Infect Dis 207:213-22. 2013..Antiretroviral therapy (ART)-mediated immune reconstitution fails to restore the capacity of the immune system to spontaneously control human immunodeficiency virus (HIV) replication...
- Effects of highly active antiretroviral therapy on HIV-1-associated oral complicationsZahida Parveen
Division of Infectious Diseases, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA
Curr HIV Res 5:281-92. 2007..Future directions envisioned by the National Institutes of Health as well as novel avenues to be explored are also presented...
- Development of co-selected single nucleotide polymorphisms in the viral promoter precedes the onset of human immunodeficiency virus type 1-associated neurocognitive impairmentLuna Li
Department of Microbiology and Immunology, Drexel University College of Medicine, 245 N 15th Street, MS 1013A, Philadelphia, PA 19102, USA
J Neurovirol 17:92-109. 2011....
- Body mass index and CD4+ T-lymphocyte recovery in HIV-infected men with viral suppression on antiretroviral therapyBrandon Palermo
Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, Philadelphia, PA, USA
HIV Clin Trials 12:222-7. 2011..To better characterize the relationship between body mass index (BMI) and CD4+ T-lymphocyte recovery in HIV disease...
- Long-Acting HIV Therapy for Injection Drug UsersJeffrey M Jacobson; Fiscal Year: 2010..We propose a novel treatment strategy involving systemic administration of long-acting antiretroviral therapy as a means to ensure effective drug delivery and viral suppression in HIV-infected populations prone to poor drug-adherence. ..